Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,826 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation: A multicenter retrospective study.
Hata T, Sakaguchi C, Hirano K, Kobe H, Ishida M, Nakano T, Tachibana Y, Tamiya N, Shiotsu S, Takeda T, Yamada T, Yokoyama T, Tsuchiya M, Nagasaka Y. Hata T, et al. Among authors: yokoyama t. Thorac Cancer. 2023 Apr;14(11):1004-1011. doi: 10.1111/1759-7714.14836. Epub 2023 Mar 3. Thorac Cancer. 2023. PMID: 36866788 Free PMC article.
Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403.
Oda N, Ichihara E, Hotta K, Ninomiya K, Ninomiya T, Kubo T, Minami D, Murakami T, Yokoyama T, Harada D, Kuyama S, Ichikawa H, Inoue K, Kishino D, Inoue M, Takigawa N, Shibayama T, Harita S, Tanimoto M, Kiura K. Oda N, et al. Among authors: yokoyama t. Clin Lung Cancer. 2017 Mar;18(2):241-244. doi: 10.1016/j.cllc.2016.07.003. Epub 2016 Jul 9. Clin Lung Cancer. 2017. PMID: 27506489 Clinical Trial.
Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).
Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y, Tamura D, Morita S, Negoro S, The Hanshin Oncology Group F. Hata A, et al. Among authors: yokoyama t. Cancer. 2018 Oct 1;124(19):3830-3838. doi: 10.1002/cncr.31678. Epub 2018 Sep 7. Cancer. 2018. PMID: 30192383 Free article. Clinical Trial.
A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
Oda N, Hotta K, Ninomiya K, Minami D, Ichihara E, Murakami T, Yokoyama T, Ichikawa H, Chikamori K, Takigawa N, Ochi N, Harita S, Maeda Y, Kiura K. Oda N, et al. Among authors: yokoyama t. Cancer Chemother Pharmacol. 2018 Dec;82(6):1031-1038. doi: 10.1007/s00280-018-3694-5. Epub 2018 Oct 1. Cancer Chemother Pharmacol. 2018. PMID: 30276451 Clinical Trial.
Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol.
Ninomiya T, Ishikawa N, Inoue K, Kubo T, Yasugi M, Shibayama T, Maeda T, Fujitaka K, Kodani M, Yokoyama T, Kuyama S, Ochi N, Ueda Y, Miyoshi S, Kozuki T, Amano Y, Kubota T, Sugimoto K, Bessho A, Ishii T, Watanabe K, Oze I, Hotta K, Kiura K. Ninomiya T, et al. Among authors: yokoyama t. Clin Lung Cancer. 2019 Mar;20(2):134-138. doi: 10.1016/j.cllc.2018.10.008. Epub 2018 Nov 1. Clin Lung Cancer. 2019. PMID: 30514667
Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial.
Nakao A, Hiranuma O, Uchino J, Sakaguchi C, Kita T, Hiraoka N, Ishizuka T, Kubota Y, Kawasaki M, Goto Y, Imai H, Hattori N, Nakatomi K, Uramoto H, Uryu K, Fukuda M, Uchida Y, Yokoyama T, Akai M, Mio T, Nagashima S, Chihara Y, Tamiya N, Kaneko Y, Mouri T, Yamada T, Yoshimura K, Fujita M, Takayama K. Nakao A, et al. Among authors: yokoyama t. Oncologist. 2019 May;24(5):593-e170. doi: 10.1634/theoncologist.2019-0003. Epub 2019 Jan 16. Oncologist. 2019. PMID: 30651400 Free PMC article. Clinical Trial.
A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302.
Ikeda S, Yoshioka H, Kaneda T, Yokoyama T, Niwa T, Sone N, Ishida T, Morita M, Tomioka H, Komaki C, Hirabayashi M, Hasegawa Y, Noguchi T, Nakano Y, Sakaguchi C, Yoshimura K, Hirai T. Ikeda S, et al. Among authors: yokoyama t. Oncology. 2019;97(6):327-333. doi: 10.1159/000501967. Epub 2019 Aug 14. Oncology. 2019. PMID: 31412347 Clinical Trial.
A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
Yokoyama T, Yoshioka H, Fujimoto D, Demura Y, Hirano K, Kawai T, Kagami R, Washio Y, Ishida T, Kogo M, Tomii K, Okuno T, Akai M, Hirabayashi M, Nishimura T, Nakahara Y, Kim YH, Miyakoshi C, Yoshimura K, Hirai T; Kyoto Thoracic Oncology Research Group (KTORG). Yokoyama T, et al. Lung Cancer. 2019 Sep;135:175-180. doi: 10.1016/j.lungcan.2019.03.030. Epub 2019 Mar 28. Lung Cancer. 2019. PMID: 31446992 Clinical Trial.
3,826 results